Noninvasive measurement of advanced glycation end product level to predict the curative effect of diabetic macular edema

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K20252
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Ophthalmology
• Research Institution: Shinshu University
• Principal Investigator: HIRANO Takao 信州大学, 医学部附属病院, 助教(特定雇用) (90735151)
• Research Collaborator: TORIYAMA Yuich 信州大学, 医学部, 助教 (90757759) ; MURATA Toshinori 信州大学, 学術研究院医学系, 教授 (50253406) ; NAGAI Ryuji 東海大学, 農学部, 教授 (20315295)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 糖尿病網膜症 / 糖尿病黄斑浮腫 / 終末糖化産物 / 血管内皮増殖因子 / 自発蛍光 / 水晶体 / 皮膚 / 非侵襲

Outline of Final Research Achievements

Diabetic macula edema (DME) causes social vision loss and it is difficult to treat DME patients. Patients with diabetes mellitus are known to have high levels of advanced glycation end products (AGEs) in the vitreous body and blood. Although Ranibizumab has good curative effect in DME treatment, several cases are difficult to treat. The examination about the factor which can foresee the curative effect is important. Recently, the devices which can measure spontaneous fluorescence of lens and skin were developed. This study aimed to examine the relationship of the spontaneous fluorescence which reflects AGE levels in DME patients and treatment-resistant to Ranibizumab. Our observations suggest that the spontaneous fluorescence which reflects AGE levels, may serve as a good indicator for treatment-resistant to Ranibizumab in DME patients

Free Research Field

網膜硝子体